论文部分内容阅读
1981年9月至1984年8月对112例肝癌进行治疗。其中单用IPPV12例,IPPV+5Fu 46例,5Fu 54例。半年生存率分别为16.7％、21.7％、7.4％,平均生存期分别为3.43月、4.39月、2.59月,临床缓解率分别为66.7％、50.0％、3.7％,本文结果表明IPPV能提高机体细胞免疫水平,单用IPPV能使临床症状得到明显改善,延长患者生命;与抗癌药物联用时能减少抗癌药物的毒副反应。表明IPPV在临床上作为一个辅助抗癌药物是值得使用的。
From September 1981 to August 1984, 112 cases of HCC were treated. Among them, 12 cases were IPPV alone, 46 cases were IPPV + 5Fu and 54 cases were 5Fu. The half-year survival rates were 16.7%, 21.7% and 7.4%, respectively. The average survival rates were 3.43 months, 4.39 months and 2.59 months, respectively. The clinical remission rates were 66.7%, 50.0% and 3.7% respectively. Immune levels, IPPV alone can significantly improve clinical symptoms, prolong the life of patients; and anti-cancer drugs can reduce the side effects of anti-cancer drugs. That IPPV is clinically useful as a secondary anticancer drug is worth using.